载脂蛋白A5与冠心病(3)
[12] Ishihara M， Kujiraoka T， Iwasaki T， et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration[J].Journal of Lipid Research， 2005，46(9)：2015-2022.
[13] Nilsson SK， Heeren J， Olivecrona G，et al. Apolipoprotein A-V； a potent triglyceride reducer[J].Atherosclerosis，2011，19(1)：15-21
[14] Niculescu LS， Vladica M， SimaAV. Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome. Biochem Biophys Res Commun. 2010；391：587–591.
[15] Huang XS， Zhao SP， Zhang Q， Bai L， Hu M. Association of plasma apolipoprotein AV with lipid profiles in patients with acute coronary syndrome. Atherosclerosis. 2009；204：e99–e102.
[16] Henneman P， Schaap FG， Havekes LM， et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis. 2007；193：129–134.
[17] Wang J， Ban MR， Kennedy BA， et al. APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med 2008；5：730–7.
[18] Hubacek JA， Wang WW， Skodova Z， Adamkova V， et al. APOA5 Ala315>Val，identi.ed in patients with severe hypertriglyceridemia， is a common mutation with no major effects on plasma lipid levels. Clin Chem Lab Med 2008；46： 773–7., http://www.100md.com(马晓东 陈立侠 曹勇沛 石怀玉 邢乐文 李永杰)
[13] Nilsson SK， Heeren J， Olivecrona G，et al. Apolipoprotein A-V； a potent triglyceride reducer[J].Atherosclerosis，2011，19(1)：15-21
[14] Niculescu LS， Vladica M， SimaAV. Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome. Biochem Biophys Res Commun. 2010；391：587–591.
[15] Huang XS， Zhao SP， Zhang Q， Bai L， Hu M. Association of plasma apolipoprotein AV with lipid profiles in patients with acute coronary syndrome. Atherosclerosis. 2009；204：e99–e102.
[16] Henneman P， Schaap FG， Havekes LM， et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis. 2007；193：129–134.
[17] Wang J， Ban MR， Kennedy BA， et al. APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med 2008；5：730–7.
[18] Hubacek JA， Wang WW， Skodova Z， Adamkova V， et al. APOA5 Ala315>Val，identi.ed in patients with severe hypertriglyceridemia， is a common mutation with no major effects on plasma lipid levels. Clin Chem Lab Med 2008；46： 773–7., http://www.100md.com(马晓东 陈立侠 曹勇沛 石怀玉 邢乐文 李永杰)